Sustainable synthesis of Hyaluronic Acid via engineered strains of non-pathogenic bacteria - from carbon dioxide and waste feedstock to low-cost, sustainable, and waste-free Hyaluronic Acid for cosmetics, medicine, and nutraceuticals

通过非致病性细菌的工程菌株可持续合成透明质酸 - 从二氧化碳和废弃原料到用于化妆品、药品和营养品的低成本、可持续且无废物的透明质酸

• 批准号: 10034038
• 金额: $ 50.97万
• 依托单位: 17CICADA LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10034038
• 关键词: Sustainable; synthesis; Hyaluronic; Acid; via

17Cicada anticipates market entry for its bacterial Hyaluronic Acid (HA) by 2025\. Our projected cumulative 5-year profits are of the order of £5.2 million (by 2029), i.e. 1033% return on investment (ROI) on project costs of £506,366 GBP.HA is widely distributed throughout connective, epithelial and neural tissues in human and animal bodies. It plays a significant range of biological roles, and is used in cosmetics (e.g. skin-moisturising and wrinkle-reducing products), cosmetic procedures (HA-based dermal fillers), medical treatment (e.g. eye surgery) and effective relief from osteoarthritis (by injecting HA into the joints).The global market for finished HA products was $20 billion in 2019 (Grand View Research), including $9b for medical products, $8b for cosmetics and $3 billion for nutraceutical products. Despite its chemical simplicity, HA-biochemistry is complex because it interacts differently with cell receptors depending on its molecular weight -- a property which paves the way for more technologically advanced medical products. The market anticipates a growth rate of 7.19% (CAGR) between Y2021-2028, driven mainly by an aging population and increasing aesthetic consciousness.Commercial HA is sourced from animals (rooster-comb) and competing, fermentation-based, non-animal products. The latter is based on bacterial cultures (especially _Streptococcus equi_) which are human pathogens. Although there is a powerful shift towards non-animal products, the use of human pathogens is problematic due to the immunogenic effect of protein/toxin residuals. This significant drawback can be greater in streptococcal-HA than in animal-sourced HA despite its low overall protein content. **It is therefore anticipated that microbial HA-production will shift towards non-pathogenic bacterial strains**.**Our vision** is a sustainable, bio-based HA which will spur medical innovation, reduce costs, abolish animal-sourced HA, and expand use of HA into stem cell therapy and tissue engineering. We envisage a revolution where small, digitally controlled HA bioreactors are operated by highly qualified personnel -- producing little or no waste, while consuming carbon and utilising less resource-intensive feedstocks.**Our key objectives** involve research on two engineered bacterial strains which are non-pathogenic, and which can consume either carbon dioxide or waste feedstocks. **We will focus** on producing HA in continuous production, coupled with robust techno-economic analyses to select the best strain for scale-up.**Our innovation** is a first-of-a-kind attempt to produce commercial HA via bacterial strains which are non-pathogenic _and_ which consume carbon dioxide and/or less resource-intensive feedstocks -- paving the way for novel nutraceuticals and lower-cost, more circular/sustainable HA-based cosmetic and medical products.

17CICADA预计到2025年，其细菌透明质酸（HA）的市场进入。我们预计的5年累计利润为520万英镑（到2029年），即投资回报率（ROI）为506,366英镑的投资回报率（ROI）。HA在人类和动物身体中广泛分布在整个结合，上皮和神经组织中。它扮演着重要范围的生物学作用，用于化妆品（例如，皮肤化和减少包裹的产品），美容程序（基于HA的皮肤填充剂），医疗治疗（例如，眼神手术）（例如，有效的骨骼疾病）和骨关节炎的术语（通过将HA注入了$ 20的BRAND HA）。产品，化妆品的$ 8B，营养产品的30亿美元。尽管具有化学性的简单性，但HA生物化学还是复杂的，因为它与细胞接收器相互作用，具体取决于其分子量 - 该特性为更高级的医疗产品铺平了道路。该市场预计，Y2021-2028之间的增长率为7.19％（CAGR），主要由人口老龄化和审美意识提高驱动。商业HA来自动物（公鸡炸弹）和竞争，基于发酵的，非动物的产品。后者是基于人类病原体的细菌培养物（尤其是_streptoccus obelent_）。尽管向非动物产物有强大的转变，但由于蛋白质/毒素残留物的免疫原性作用，人类病原体的使用是有问题的。在链球菌中，这种显着的缺点可能比动物为HA目的地的总体蛋白质含量低。 **因此，预计微生物HA的产生将转向非致病细菌菌株**。我们设想了一场革命，在该革命中，小型，数字控制的HA生物反应器由高素质的人员运营 - 几乎没有或没有浪费，同时消耗碳并利用较少的资源密集型原料。 **我们将专注于连续生产中的生产HA，再加上强大的技术经济分析，以选择最佳的扩展压力。低成本，基于HA的更低/可持续的化妆品和医疗产品。